Bernini F, Via D P, Bocan T M, Gotto A M, Smith L C
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Arteriosclerosis. 1988 Nov-Dec;8(6):825-31. doi: 10.1161/01.atv.8.6.825.
We have previously reported that Fab fragments of IgGs modified by lactosamination (lac-Fab) can direct macromolecules, including low density lipoproteins (LDL), to the liver. In the present paper we demonstrate that lac-Fab that is specific for LDL is an effective and selective hypolipoprotein agent. A plasma pool of about 60 mg/dl of apoprotein B (apo B) was induced in rats by bolus injection of human LDL (hLDL), which increased the cholesterol value to about 150 mg/dl. Three hours after injection of the highest dose of lac-Fab, the total cholesterol decreased to 80 mg/dl, compared to 120 mg/dl in control animals. Studies conducted with 131I-tyramine-cellobiose-labeled LDL indicated that the liver was the only organ in which lac-Fab increased LDL uptake and degradation. The effect of lac-Fab was dose-dependent. With amounts of lac-Fab between 13 to 42 mg/kg body weight, the amount of hLDL cleared through the lac-Fab mechanism ranged from 30% to 70% of the initial pool. Analysis of the plasma lipoprotein subfractions revealed that high density lipoprotein levels were not affected. Histologic examination of liver sections after sequential injection of fluorescently labeled hLDL and lac-Fab indicated specific uptake in the hepatocytes when compared to control sections obtained from animals injected with Dil-LDL alone. The uptake of fluorescent LDL induced by lac-Fab was completely prevented by a co-injection of an excess of asialofetuin. We conclude that lac-Fab that is specific for LDL is a selective hypolipoproteinemic agent and a specific carrier to the hepatocytes.
我们之前曾报道,经乳糖胺化修饰的IgG的Fab片段(乳糖胺化-Fab,lac-Fab)可将包括低密度脂蛋白(LDL)在内的大分子导向肝脏。在本文中,我们证明对LDL具有特异性的lac-Fab是一种有效且具有选择性的降脂蛋白剂。通过大剂量注射人LDL(hLDL)在大鼠中诱导出约60mg/dl载脂蛋白B(apo B)的血浆池,这使胆固醇值增加到约150mg/dl。注射最高剂量的lac-Fab三小时后,总胆固醇降至80mg/dl,而对照动物为120mg/dl。用131I-酪胺-纤维二糖标记的LDL进行的研究表明,肝脏是lac-Fab增加LDL摄取和降解的唯一器官。lac-Fab的作用呈剂量依赖性。当lac-Fab的量在13至42mg/kg体重之间时,通过lac-Fab机制清除的hLDL量占初始血浆池的30%至70%。对血浆脂蛋白亚组分的分析显示高密度脂蛋白水平未受影响。在依次注射荧光标记的hLDL和lac-Fab后,对肝脏切片进行组织学检查,结果表明与仅注射Dil-LDL的动物的对照切片相比,肝细胞中有特异性摄取。预先注射过量的去唾液酸胎球蛋白可完全阻止lac-Fab诱导的荧光LDL的摄取。我们得出结论,对LDL具有特异性的lac-Fab是一种选择性降血脂剂,也是肝细胞的特异性载体。